Atria Investments Inc Sells 991 Shares of Haemonetics Co. (NYSE:HAE)

Atria Investments Inc cut its stake in Haemonetics Co. (NYSE:HAE) by 23.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,221 shares of the medical instruments supplier’s stock after selling 991 shares during the period. Atria Investments Inc’s holdings in Haemonetics were worth $259,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Quarry LP acquired a new position in shares of Haemonetics during the second quarter valued at about $39,000. Daiwa Securities Group Inc. bought a new position in Haemonetics during the second quarter valued at about $82,000. Canada Pension Plan Investment Board acquired a new position in Haemonetics in the 2nd quarter valued at approximately $83,000. Nisa Investment Advisors LLC lifted its position in shares of Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 632 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Haemonetics during the 2nd quarter worth approximately $140,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HAE has been the subject of a number of recent research reports. Barrington Research restated an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research note on Friday, November 8th. Bank of America initiated coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective for the company. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $112.00 price objective on shares of Haemonetics in a report on Friday, November 15th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Stock Performance

NYSE HAE opened at $85.55 on Friday. Haemonetics Co. has a 1-year low of $70.25 and a 1-year high of $97.97. The company has a 50 day moving average of $78.75 and a 200-day moving average of $82.40. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of 35.50, a PEG ratio of 1.33 and a beta of 0.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. During the same period in the prior year, the company earned $0.99 EPS. Haemonetics’s revenue for the quarter was up 8.6% on a year-over-year basis. On average, equities analysts forecast that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.